Blog Band - Page 31 of 299

08

Shots: The US FDA has granted FTD to Birelentinib (DZD8586) for the treatment of adults with r/r chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received ≥2L of…

08

Aug 2025

VIDEO

LIFE SCIENCES | DAILY NEWS | AUG 08, 2025 | PHARMASHOTS

08

Aug 2025

NEWS

Genmab Reports P-III (EPCORE FL-1) Trial Data on Epcoritamab for R/R Follicular Lymphoma

Shots: Genmab has reported P-III (EPCORE FL-1) trial data assessing epcoritamab (SC) + rituximab & lenalidomide (R2) vs R2 alone for the treatment of adult patients with r/r follicular lymphoma…

08

Aug 2025

NEWS

Syndicate of Global Investors to Acquire HistoSonics for $2.25B

Shots: A management-led syndicate, supported by global investors, will acquire a majority stake in HistoSonics for $2.25B The acquisition was led by K5 Global, Bezos Expeditions, Wellington Management, Alpha JWC…

08

Aug 2025

NEWS

Sebela Pharmaceuticals Reports P-III (TRIUMpH) Program Completion and Data on Tegoprazan for Gastroesophageal Reflux Disease (GERD)

Shots: TRIUMpH program consisted of 2 P-III trials assessing tegoprazan in US GERD pts with erosive esophagitis (EE; n=1250 incl. 463 with LA Grade C/D esophagitis) & non-erosive reflux disease…

08

Aug 2025

NEWS

DoveTree Medicines Enters a ~$5.99B Deal with XtalPi to Discover Novel Therapeutics Across Various Indications

Shots: XtalPi has entered into a strategic collaboration with DoveTree Medicines to identify novel therapeutics across oncology, immunology, inflammation, neurology, & metabolic diseases, leveraging XtalPi's de novo drug discovery platform…

08

Aug 2025

NEWS

Celltrion Secures the US FDA’s Approval for Avtozma IV (Biosimilar, Actemra) to Treat Cytokine Release Syndrome

Shots: The US FDA has approved Avtozma IV, a biosimilar to Actemra (tocilizumab), for treating cytokine release syndrome in pts (≥2yrs.), covering all Actemra IV-approved indications in the US; expected…

07

Aug 2025

INSIGHTS+

Know Your Investor: Venrock Healthcare Capital Partners (August’25 Edition)  

Shots:    Welcome to the August edition of Know Your Investor, featuring leading venture capital firms fuelling innovation in healthcare and life sciences This edition spotlights Venrock Healthcare Capital Partners, a…

07

Aug 2025

NEWS

Flare Therapeutics Reports First Patient Dosing in P-Ib Trial of FX-909 for Urothelial Cancer

Shots: Flare Therapeutics has dosed its first patient with FX-909 in P-Ib trial for the treatment of locally-advanced or metastatic urothelial cancer The P-Ib trial will assess FX-909 (30 &…

07

Aug 2025

NEWS

Fapon Biopharma Reports First Patient Enrolment in P-I Trial of FP008 for Solid Tumors

Shots: Fapon Biopharma has enrolled the first patient in China for its P-I trial of FP008 for advanced solid tumors, conducted at Zhejiang Cancer Hospital. The patient completed the DLT…

The US FDA Grants Fast Track Designation to Dizal’s Birelentinib for Treating R/R CLL/SLL

LIFE SCIENCES | DAILY NEWS | AUG 08, 2025 | PHARMASHOTS

Genmab Reports P-III (EPCORE FL-1) Trial Data on Epcoritamab for R/R Follicular Lymphoma

Syndicate of Global Investors to Acquire HistoSonics for $2.25B

Sebela Pharmaceuticals Reports P-III (TRIUMpH) Program Completion and Data on Tegoprazan for Gastroesophageal Reflux Disease (GERD)

DoveTree Medicines Enters a ~$5.99B Deal with XtalPi to Discover Novel Therapeutics Across Various Indications

Celltrion Secures the US FDA’s Approval for Avtozma IV (Biosimilar, Actemra) to Treat Cytokine Release Syndrome

Know Your Investor: Venrock Healthcare Capital Partners (August’25 Edition)

Flare Therapeutics Reports First Patient Dosing in P-Ib Trial of FX-909 for Urothelial Cancer

Fapon Biopharma Reports First Patient Enrolment in P-I Trial of FP008 for Solid Tumors

Contact US

OUR INFORMATION

FOLLOW US